All In Biotech

Free tool

FAERS Monitor: Etopophos Preservative Free

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020457 or its brand name (Etopophos Preservative Free, Etoposide Phosphate). Reports on generic versions are filed under their own applications.

Reports

1,635

Serious

1,491

91% of reports

Hospitalization

592

Death reported

296

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use200
  • disease progression163
  • product use in unapproved indication93
  • acute kidney injury83
  • thrombocytopenia82
  • febrile neutropenia72
  • pyrexia71
  • drug ineffective68
  • malignant neoplasm progression68
  • neutropenia61
  • product storage error61
  • anaemia59
  • pancytopenia59
  • death54
  • mucosal inflammation54

Reports by year received

View as table
YearReports
20046
20054
200610
200711
20103
201219
201357
201452
201568
2016126
201786
2018182
2019164
202095
2021107
2022151
2023188
2024138
2025102
202666

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,524 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mucosal inflammationSignal5426.620.41,303
disease progressionSignal16317.715.32,570
febrile neutropeniaSignal7214.011.2856
pancytopeniaSignal5913.610.6677
thrombocytopeniaSignal829.47.6613
product storage errorSignal619.07.0425
malignant neoplasm progressionSignal688.56.8448
acute kidney injurySignal837.05.7422
neutropeniaSignal615.84.5237
product use in unapproved indicationSignal934.84.0282
anaemiaSignal594.03.1130
off label useSignal2002.92.6265
pyrexiaSignal712.62.172
death540.80.62
drug ineffective680.70.512

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.